BIOTRONIK Announces First U.S. Commercial Implant of Solia CSP S, World’s First Pacing Lead Specifically Designed for LBBAP
BIOTRONIK, a global leader in cardiovascular medical technology, today announced the first commercial implant of the Solia CSP S pacing lead, marking its first use in routine clinical practice following U.S. Food and Drug Administration (FDA) approval. The procedure was successfully completed by Xiaodong (Andy) Zhang, MD, PhD, Director, Moses EP Lab, Montefiore Health System, New York.
“Left bundle branch area pacing offers many physiological and clinical benefits for patients but has been historically constrained by the use of legacy pacing leads,” said Dr. Zhang. “The Solia CSP S lead has been an important step forward for these procedures, and I am grateful to be the first to implant this commercially in the USA.”
“We are very proud to be the first to introduce Solia CSP in the United States, as this reinforces our dedication to providing innovative technologies," said Luigi Di Biase, MD, PhD, System Director Electrophysiology and Director of Arrhythmia Services, Montefiore Medical Center and Professor of Medicine at the Albert Einstein College of Medicine, New York.
Solia CSP S is the world’s first pacing lead to combine the support of a stylet-driven lead platform with the efficiency of a fixed helix – specifically engineered for LBBAP procedures. The lead’s optimized helix, enhanced steerability, and simplified handling are designed to reduce preparation time while improving procedural efficiency and ease of delivery.
“By offering a pacing lead designed specifically for LBBAP, Solia CSP S has the potential to make physiologic pacing more consistent and reproducible in everyday clinical practice, supporting improved electrical synchrony and patient outcomes,” said David Hayes, MD, Chief Medical Officer, BIOTRONIK.
“CSP represents the future of physiologic pacing, and Solia CSP S is the first of a new generation of LBBAP-specific solutions,” said Ryan Walters, President, BIOTRONIK. “It reflects our focus on delivering purpose‑built technologies that empower clinicians and elevate the standard of care for patients around the world.”
For more information about Solia CSP S and BIOTRONIK’s LBBAP portfolio, please visit www.biotronik.com.
About BIOTRONIK
For over 60 years, BIOTRONIK has stood at the forefront of medical technology, pioneering breakthrough innovations that are transforming the lives of millions affected by heart disease and chronic pain. Rooted in a deep purpose to seamlessly harmonize technology with the human body, we engineer trusted, life-changing therapies through our advanced active implants in Cardiac Rhythm Management, Monitoring, and Neuromodulation, while providing cutting-edge solutions in Electrophysiology. From creating Germany’s first pacemaker in 1963 to breaking new ground in digital technologies and Conduction System Pacing today, BIOTRONIK is continuously raising the bar for quality, performance, and innovation. Headquartered in Berlin, our global reach spans over 100 countries across the Americas, EMEA, and Asia—bringing bold, future-ready solutions that are shaping the next generation of medical technology.